Literature DB >> 35218460

Weight gain after in vitro fertilization: a potential consequence of controlled ovarian stimulation.

Simar S Bajaj1, Bhav Jain2, Fatima Cody Stanford3,4.   

Abstract

In the USA, 42% of adult women were estimated to have obesity, and 13% of women of childbearing age similarly have impaired fecundity. Obesity is associated with infertility such that patients with obesity often seek out in vitro fertilization (IVF) services. Here, we report on the case of a woman with childhood-onset class II obesity who had been undergoing treatment with phentermine and topiramate prior to undergoing 3 cycles of IVF. With each cycle, the patient temporarily gained 13-15 lbs. during controlled ovarian stimulation (COS). Weight gain from COS may be clinically relevant and merits further study to optimize weight status across women's reproductive life and to better assist women who gain weight secondary to IVF. Incorporating weight monitoring into IVF protocols may also help better characterize the scope of weight gain from COS.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Mesh:

Year:  2022        PMID: 35218460      PMCID: PMC9051006          DOI: 10.1007/s10815-022-02444-w

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.357


  22 in total

Review 1.  Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis.

Authors:  Luis Varela; Tamas L Horvath
Journal:  EMBO Rep       Date:  2012-11-13       Impact factor: 8.807

Review 2.  Stress and Obesity.

Authors:  A Janet Tomiyama
Journal:  Annu Rev Psychol       Date:  2018-06-21       Impact factor: 24.137

3.  Pharmacological management of obesity: an endocrine Society clinical practice guideline.

Authors:  Caroline M Apovian; Louis J Aronne; Daniel H Bessesen; Marie E McDonnell; M Hassan Murad; Uberto Pagotto; Donna H Ryan; Christopher D Still
Journal:  J Clin Endocrinol Metab       Date:  2015-01-15       Impact factor: 5.958

4.  Use of prescription medications associated with weight gain among US adults, 1999-2018: A nationally representative survey.

Authors:  Craig M Hales; Qiuping Gu; Cynthia L Ogden; Susan Z Yanovski
Journal:  Obesity (Silver Spring)       Date:  2021-12-14       Impact factor: 9.298

Review 5.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

6.  Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women.

Authors:  Jan Willem van der Steeg; Pieternel Steures; Marinus J C Eijkemans; J Dik F Habbema; Peter G A Hompes; Jan M Burggraaff; G Jur E Oosterhuis; Patrick M M Bossuyt; Fulco van der Veen; Ben W J Mol
Journal:  Hum Reprod       Date:  2007-12-11       Impact factor: 6.918

7.  Controlled ovarian hyperstimulation leads to high progesterone and estradiol levels during early pregnancy.

Authors:  Ilkka Y Järvelä; Sari Pelkonen; Outi Uimari; Kaarin Mäkikallio; Katri Puukka; Aimo Ruokonen; Aydin Tekay; Hannu Martikainen
Journal:  Hum Reprod       Date:  2014-09-08       Impact factor: 6.918

8.  Ovarian hyperstimulation syndrome.

Authors:  Pratap Kumar; Sameer Farouk Sait; Alok Sharma; Mukesh Kumar
Journal:  J Hum Reprod Sci       Date:  2011-05

9.  Serum estradiol levels in controlled ovarian stimulation directly affect the endometrium.

Authors:  Kamran Ullah; Tanzil Ur Rahman; Hai-Tao Pan; Meng-Xi Guo; Xin-Yan Dong; Juan Liu; Lu-Yang Jin; Yi Cheng; Zhang-Hong Ke; Jun Ren; Xian-Hua Lin; Xiao-Xiao Qiu; Ting-Ting Wang; He-Feng Huang; Jian-Zhong Sheng
Journal:  J Mol Endocrinol       Date:  2017-05-24       Impact factor: 5.098

Review 10.  It is not justified to reject fertility treatment based on obesity.

Authors:  Aafke Koning; Ben Willem Mol; Wybo Dondorp
Journal:  Hum Reprod Open       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.